Lamivudine


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Lactation.
Special Precautions
Patient w/ hepatomegaly, hepatitis or other risk factors for hepatic disease; childn w/ history or risk factors for pancreatitis. Pregnancy. Monitoring Parameters Monitor amylase, bilirubin, liver enzymes 3 mthly during therapy; haematologic parameters, HIV viral load, CD4 count; signs and symptoms of pancreatitis or hepatonecroinflammation; hepatitis B virus (HBV) DNA regularly during therapy. Monitor hepatic function for several mth following discontinuation of therapy. Perform HIV testing prior to and periodically during treatment.
Adverse Reactions
Abdominal pain, nausea, vomiting, diarrhoea, headache, fever, rash, alopecia, malaise, insomnia, cough, nasal symptoms, arthralgia, musculoskeletal pain, pancreatitis, anaemia, neutropenia, thrombocytopenia, immune reconstitution syndrome, lipodystrophy, metabolic abnormalities (e.g. hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia, hyperlactataemia), osteonecrosis; increased creatine phosphokinase, liver enzymes and serum amylase. Rarely, rhabdomyolysis.
Potentially Fatal: Lactic acidosis, hepatomegaly w/ steatosis.
Drug Interactions
Decreased renal excretion w/ high-dose trimethoprim. Severe anaemia may occur when used concomitantly w/ zidovudine. Treatment failure and emergence of resistance may result from once daily triple regimens of lamivudine and tenofovir w/ either abacavir or didanosine. May antagonise the antiviral action of zalcitabine. May enhance the adverse effect of emtricitabine.
CIMS Class
Antivirals
ATC Classification
J05AF05 - lamivudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on lamivudine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in